Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013
- PMID: 25258101
- DOI: 10.1016/j.vaccine.2014.09.018
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013
Abstract
Background: Trivalent live attenuated influenza vaccine (LAIV3) was licensed and recommended for use in 2003 in children and adults 2-49 years of age. Post-licensure safety data have been limited, particularly in adults.
Methods: We searched Vaccine Adverse Event Reporting System (VAERS) for US reports after LAIV3 from July 1, 2005-June 30, 2013 (eight influenza seasons) in adults aged ≥ 18 years old. We conducted descriptive analyses and clinically reviewed serious reports (i.e., death, life-threatening illness, hospitalization, prolonged hospitalization, or permanent disability) and reports of selected conditions of interest. We used empirical Bayesian data mining to identify adverse events (AEs) that were reported more frequently than expected. We calculated crude AE reporting rates to VAERS by influenza season.
Results: During the study period, VAERS received 1207 LAIV3 reports in adults aged 18-49 years old; 107 (8.9%) were serious, including four death reports. The most commonly reported events were expired drug administered (n=207, 17%), headache (n=192, 16%), and fever (n=133, 11%). The most common diagnostic categories for non-fatal serious reports were neurological (n=40, 39%), cardiovascular (n=14, 14%), and other non-infectious conditions (n=20, 19%). We noted a higher proportion of Guillain-Barré syndrome (GBS) and cardiovascular reports in the Department of Defense (DoD) population compared to the civilian population. Data mining detected disproportional reporting of ataxia (n=15); clinical review revealed that ataxia was a component of diverse clinical entities including GBS.
Conclusions: Review of VAERS reports are reassuring, the only unexpected safety concern for LAIV3 identified was a higher than expected number of GBS reports in the DoD population, which is being investigated. Reports of administration of expired LAIV3 represent administration errors and indicate the need for education, training and screening regarding the approved indications.
Keywords: Live attenuated influenza vaccine; Post-licensure surveillance; Vaccine safety.
Published by Elsevier Ltd.
Comment in
-
Use of Live Attenuated Influenza Vaccine in Children With Egg Allergy and Asthma.J Pediatric Infect Dis Soc. 2015 Mar;4(1):81-2. doi: 10.1093/jpids/piu116. Epub 2014 Dec 26. J Pediatric Infect Dis Soc. 2015. PMID: 26407364 No abstract available.
Similar articles
-
Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9. Vaccine. 2015. PMID: 25678241
-
Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.J Pediatric Infect Dis Soc. 2015 Sep;4(3):205-13. doi: 10.1093/jpids/piu034. Epub 2014 May 7. J Pediatric Infect Dis Soc. 2015. PMID: 26407428
-
Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.Vaccine. 2019 Mar 7;37(11):1516-1520. doi: 10.1016/j.vaccine.2019.01.052. Epub 2019 Feb 7. Vaccine. 2019. PMID: 30739795
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
-
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019.Vaccine. 2020 Aug 18;38(37):5923-5926. doi: 10.1016/j.vaccine.2020.07.007. Epub 2020 Jul 21. Vaccine. 2020. PMID: 32709434 Review.
Cited by
-
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022. Front Immunol. 2022. PMID: 35185881 Free PMC article.
-
Guillain-Barré syndrome and influenza vaccines: current evidence.Rev Esp Quimioter. 2019 Aug;32(4):288-295. Epub 2019 Jun 20. Rev Esp Quimioter. 2019. PMID: 31232571 Free PMC article.
-
Value of an in-depth analysis of unpublished data on the safety of influenza vaccines in pregnant women.Vaccine. 2017 Oct 27;35(45):6154-6159. doi: 10.1016/j.vaccine.2017.09.049. Epub 2017 Sep 27. Vaccine. 2017. PMID: 28958812 Free PMC article.
-
Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.Vaccine. 2016 Aug 17;34(37):4406-14. doi: 10.1016/j.vaccine.2016.07.019. Epub 2016 Jul 19. Vaccine. 2016. PMID: 27449076 Free PMC article.
-
Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England.Drug Saf. 2016 Apr;39(4):323-33. doi: 10.1007/s40264-015-0384-7. Drug Saf. 2016. PMID: 26798051 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical